| Literature DB >> 31091119 |
Zhiqiang Chen1,2, Peng Yuan1,2, Xifeng Sun1,2, Kun Tang1,2, Haoran Liu1,2, Shanfu Han1,2, Tao Ye1,2, Xiao Liu1,2, Xiaoqi Yang1,2, Jin Zeng1,2, Libin Yan1,2, Jinchun Xing3, Kefeng Xiao4, Zhangqun Ye1,2, Hua Xu1,2.
Abstract
Interaction of pioglitazone (PGZ) and macrophages (Mps) in renal crystal formation remains unclear. In the present study, we investigated the possible mechanisms involved with Mps of PGZ in suppressing renal crystal formation. Crystal formation in the mouse kidney was detected using polarized light optical microscopy and Pizzolato staining. Gene expression was detected by Western blot analysis, quantitative RT-PCR, immunohistochemistry, immunofluorescence, and ELISA. Mp phenotypes were identified by flow cytometric analysis. Cell apoptosis was detected with TUNEL assay, and tubular injury was detected with periodic acid-Schiff staining. Interaction of peroxisome proliferator-activated receptor (PPAR)-γ and promoter was determined by chromatin immunoprecipitation assay. Luciferase reporter assay was performed to authenticate target genes of miRNA-23 (miR-23). Recombinant adenovirus was used to elucidate the role of miR-23 in vivo. Renal crystal formation, inflammation, tubular injury, and cell apoptosis were significantly marked in glyoxylic acid-treated groups and significantly decreased in PGZ-treated groups. PGZ significantly reduced Mp infiltration and M1 Mp polarization in the kidney. In vitro, PGZ shifted crystal-stimulated M1-predominant Mps to M2-predominant Mps, which were anti-inflammatory. PPAR-γ could directly bind to one PPAR-γ regulatory element in the promoter of pre-miR-23 to promote expression of miR-23 in Mps. We identified two downstream target genes of miR-23, interferon regulatory factor 1 and Pknox1. Moreover, miR-23 decreased crystal deposition, M1 Mp polarization, and injury in the kidney. This study has proven that PGZ decreased renal calcium oxalate crystal formation and renal inflammatory injury by suppressing M1 Mp polarization through a PPAR-γ-miR-23-interferon regulatory factor 1/Pknox1 axis. PGZ is liable to be a potential therapeutic medicine for treating urolithiasis.Entities:
Keywords: hyperoxaluria; inflammation; macrophage activation; microRNA; peroxisome proliferator-activated receptor-γ
Mesh:
Substances:
Year: 2019 PMID: 31091119 DOI: 10.1152/ajprenal.00047.2019
Source DB: PubMed Journal: Am J Physiol Renal Physiol ISSN: 1522-1466